By Nana Karikari, Senior Global Affairs Correspondent
The Food and Drugs Authority (FDA) has issued an urgent public health alert following the discovery of falsified HIV diagnostic kits circulating in Ghana. This development has triggered immediate concerns regarding the accuracy of test results and the potential for delayed clinical interventions.
The Authority identified the counterfeit products as VISITECT CD4 Advanced Disease test kits bearing lot number 0001586. These kits are confirmed to be fraudulent and do not meet the rigorous safety standards required for medical diagnostics.
Discrepancies in Manufacturer Verification
Investigations by the FDA revealed significant inconsistencies regarding the origin of the seized products. The counterfeit kits incorrectly list Omega Diagnostics Limited as the manufacturer. While Omega formerly owned the product line, the business was sold in 2022.
Official records confirm that genuine VISITECT CD4 test kits are now produced exclusively by AccuBio Limited. Legitimate products currently in circulation carry lot number 0002172 and include verified product specifications. The misidentification of the manufacturer serves as a primary indicator of the kits’ illicit nature.
Chronological Inconsistencies and Expiry Data
Authorities pointed out clear inconsistencies in the dates printed on the falsified packaging. The fake versions list a manufacturing date of August 2024 and an expiration date of January 2027. This contradicts the data on original kits, which were manufactured in July 2025 and expire in November 2026. The FDA noted that such differences in manufacturer information and dates should serve as warning signs for both distributors and end-users.
Implications for Public Health and Patient Care
The Authority stated that the presence of falsified HIV test kits poses a serious threat to public health. The VISITECT CD4 assay is a critical triage tool used to identify “advanced disease”—patients whose immune systems are severely compromised with a CD4 count below 200. Reliable diagnostics are the cornerstone of effective HIV management and any error can have major consequences.
Inaccurate readings may result in false-positive outcomes that cause unnecessary fear. More critically, false negatives could delay life-saving treatment for individuals living with the virus. This incident mirrors global warnings from the World Health Organization regarding the rise of substandard and falsified medical products in emerging markets.
Emergency Directives for Healthcare Providers
The FDA has initiated immediate protocols to mitigate the risk to the population. It has directed all hospitals, laboratories, and testing centers to audit their current inventory of VISITECT CD4 test kits. The Authority warned that any kits with lot number 0001586 must be removed from use at once. Healthcare providers are instructed to surrender these products to the nearest FDA office for professional disposal.
Surveillance and Accountability Measures
Ongoing investigations aim to trace the supply chain of these counterfeit diagnostics to hold the responsible parties accountable. The FDA is calling for increased vigilance across the health sector to prevent further distribution.
Health professionals and the public are encouraged to report any suspected medical products through official regulatory channels including the MedSafety App or the FDA’s hotlines. “Your health is too important to risk,” the FDA stated while urging the public to verify all medical products before use.
By maintaining rigorous surveillance and transparency, the Authority seeks to protect the integrity of the national healthcare system and ensure that patients receive only validated, high-quality medical devices.
